Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data ‘Looks Good’, Says Chief Scientist

2 min read

covid19

Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data ‘Looks Good’, Says Chief Scientist

news 1 day ago

New Delhi: The much-awaited approval for indigenous jab Covaxin developed by Hyderabad-based manufacturer Bharat Biotech from World...

Bharat Biotech’s Covaxin Found To Be 77.8% Effective In Final Analyis Of Phase III Trials

2 min read

covid19

Bharat Biotech’s Covaxin Found To Be 77.8% Effective In Final Analyis Of Phase III Trials

news 1 week ago

Hyderabad: Bharat Biotech, the biotechnology firm on Saturday announced the efficacy and safety of the indigenous vaccine...

Covaxin Effectively Neutralises Covid-19’s Alpha & Delta Variant: US Health Research Institute

3 min read

World news

Covaxin Effectively Neutralises Covid-19’s Alpha & Delta Variant: US Health Research Institute

news 1 week ago

The United States National Institute of Health (NIH) has said India’s Covid-19 vaccine Covaxin effectively neutralises both...

‘Pricing Clearly Established’: Bharat Biotech On Brazil Covaxin Deal Controversy

1 min read

covid19

‘Pricing Clearly Established’: Bharat Biotech On Brazil Covaxin Deal Controversy

news 1 week ago

New Delhi: Asserting that a “step-by-step” approach was followed towards contracts and regulatory approvals during an eight-month-long...

Brazil Govt Faces Probe For Choosing Bharat Biotech’s Covaxin Over ‘Cheaper’ Pfizer Vaccine

2 min read

covid19

Brazil Govt Faces Probe For Choosing Bharat Biotech’s Covaxin Over ‘Cheaper’ Pfizer Vaccine

news 2 weeks ago

New Delhi: Congressman Luis Miranda and his brother Luis Ricardo Miranda, who raised suspicions about Brazil’s vaccine...

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

1 min read

covid19

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

news 3 weeks ago

New Delhi: The result for Phase 3 clinical trial of Bharat Biotech’s Covaxin vaccine is out as...

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

1 min read

covid19

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

news 3 weeks ago

New Delhi: The result for Phase 3 clinical trial of Bharat Biotech’s Covaxin vaccine is out as...

1 min read

states

Bharat Biotech gets CISF security cover at its Hyderabad unit

news 4 weeks ago

Hyderabad: The Central Industrial Security Force (CISF) on Monday (June 14) took over the security of Bharat...

2 min read

covid19

Covaxin Effective Against Covid Variants Found In India & UK: Bharat Biotech

news 2 months ago

Vaccine maker Bharat Biotech on Sunday claimed that the indigenously produced Covid-19 vaccine ‘Covaxin’ has been found...

2 min read

India news

Bharat Biotech’s Covaxin effective against new COVID-19 variants, reveals study

news 2 months ago

New Delhi: In a recent development, a study conducted by Clinical Infectious Diseases in collaboration with National...

2 min read

states

Maharashtra to raise its oxygen production capacity to 3,000 MT, says Ajit Pawar

news 2 months ago

Mumbai: Maharashtra Deputy Chief Minister Ajit Pawar on Friday (May 14) said the state government has set a target...

2 min read

India news

Bharat Biotech’s Covaxin gets approval for phase 2/3 trials on 2-18 year-olds

news 2 months ago

New Delhi: The Hyderabad-based Bharat Biotech’s COVID-19 vaccine Covaxin has got the necessary approval from an expert...

Bharat Biotech

Covaxin Closer To WHO Approval? Covid-19 Vaccine Trial Data ‘Looks Good’, Says Chief Scientist

Bharat Biotech’s Covaxin Found To Be 77.8% Effective In Final Analyis Of Phase III Trials

Covaxin Effectively Neutralises Covid-19’s Alpha & Delta Variant: US Health Research Institute

‘Pricing Clearly Established’: Bharat Biotech On Brazil Covaxin Deal Controversy

Brazil Govt Faces Probe For Choosing Bharat Biotech’s Covaxin Over ‘Cheaper’ Pfizer Vaccine

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

Covaxin Phase 3 Trial Data Shows 77.8% Efficacy, Gets Approval From DCGI’s Expert Panel

Bharat Biotech gets CISF security cover at its Hyderabad unit

FDA rejects emergency use authorisation for Covaxin in a setback for India-made jab

Covid Vaccine Prices To Be Revised, Centre In Talks With Serum Institute & Bharat Biotech: Sources

Early Covaxin Study Shows Protections Against Beta & Delta Variants Of Covid-19

COVID Alert: Delhi left with 3,190 vaccine doses for 18-44 age group

Covaxin Effective Against Covid Variants Found In India & UK: Bharat Biotech

Bharat Biotech’s Covaxin effective against new COVID-19 variants, reveals study

Maharashtra to raise its oxygen production capacity to 3,000 MT, says Ajit Pawar

COVID-19 vaccine comparison: Know all about Covishield, Covaxin, Sputnik V ahead of vaccination

Bharat Biotech ready to share Covaxin formula with other manufacturers, says Centre

COVID-19 vaccine: Bharat Biotech ready to share formula of Covaxin with other manufacturers, says Centre

Govt Aims To Vaccinate All Citizens By Year-End, Targets 216 Cr Doses By Dec – Check Rollout Plan

Government panel recommends 12-16 week gap between Covishield doses, no change for Covaxin

50 employees of Bharat Biotech test COVID-19 positive; Joint MD’s tweet sparks concern

Bharat Biotech’s Covaxin gets DGCI nod to conduct clinical trials on children above 2 years

COVID Vaccine: DCGI Approves Phase 2/3 Clinical Trial Of Covaxin In Age Group Of 2 To 18 Yrs

Bharat Biotech to manufacture 2 crore doses of Covaxin at UP’s Bulandshahr plant every month

COVID-19 vaccination for 18-44 age group halted in these states, know the reasons behind the decision

BJP Clears Air On Centre’s Vaccine Export, Says 84% Doses Sent Abroad Part Of Licensing Liabilities

Vaccine Shortage: SII To Ramp Up Production To 10 Cr Doses By Aug, Bharat Biotech Promises 7.8 Cr Jabs

Covaxin Centres In Delhi Closed As Bharat Biotech Refused To Supply Vaccines On Centre’s Directive: AAP

Bharat Biotech Gets Approval To Start Next Phase Of Clinical Trials Of ‘Covaxin’ On Children Aged 2-18 Years

Fresh Orders Placed To Procure Covid-19 Vaccines, To Be Delivered By July: Hardeep Singh Puri

Bharat Biotech’s Covaxin gets approval for phase 2/3 trials on 2-18 year-olds